Steve Chaplin, Geoffrey M Dusheiko
Abstract
Open-access reader
Abstract Boceprevir and telaprevir are new antiviral drugs indicated for the treatment of chronic hepatitis C genotype 1 infection. In our New products review, Steve Chaplin presents the clinical data relating to their efficacy and adverse effects and Professor Geoffrey Dusheiko discusses their place in treatment.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Abstract Boceprevir and telaprevir are new antiviral drugs indicated for the treatment of chronic hepatitis C genotype 1 infection. In our New products review, Steve Chaplin presents the clinical data relating to their efficacy and adverse effects and Professor Geoffrey Dusheiko discusses their place in treatment.
Key concepts: Telaprevir, Boceprevir, Medicine, Chronic hepatitis, Adverse effect, Virology, Intensive care medicine, Internal medicine